Phase I, First in Human Trial Evaluating BI 1387446 Alone and in Combination With BI 754091 in Solid Tumors
Latest Information Update: 18 Jun 2025
At a glance
- Drugs BI 1387446 (Primary) ; Ezabenlimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim
Most Recent Events
- 02 Apr 2024 Status changed from active, no longer recruiting to completed.
- 12 Dec 2023 Planned End Date changed from 29 Mar 2024 to 17 Apr 2024.
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress